Curis, Inc. (NASDAQ:CRIS) has announced the enrolment and dosing of the first mesothelioma patient in the first phase of the CA-170 study. CA-170 is a dual inhibitor of PD1 and VISTA that gets administered orally, and Curis believe that the drug could be beneficial in the treatment of tumors that express high levels of VISTA. VISTA is shown in over 90% of the mesothelioma cells.
Enrolment ahead of schedule
Curis previously announced that they were expecting to start enrolment of patients with mesothelioma in a dedicated cohort within the on-going first phase of the study. Speaking on the progress that they have made, the CEO and President of Curis, James Dentzer, stated that they were pleased to announce the start of dosing in the CA-170 which he says is ahead of schedule.
During the last quarter’s earnings conference call, he said the company outlined the reorganization of their resources with a focus in strengthening their clinical execution. He adds that the announcement on the progress is a result of the efforts they have put in place and he reiterated that they are confident in their expectation to provide preliminary efficacy data by the second half of the year.
Positive preliminary CA-170 results
The company says that CA-170 is the only anti-VISTA therapeutic that is currently under evaluation in clinical trials. CA-170 has shown promising results in that it demonstrated encouraging safety and tolerability and also its preliminary anti-tumor activity has been favorable in various patients in different types of tumors. The first phase of the study is the CA-170 clinical trial that is targeting patient population that has shown high expression levels of VISTA. VISTA is considered to be a resistance mechanism in anti-PD1 Antibodies treatment in melanoma as well as in prostate cancer among other cancers.
The first phase will be an open-label dose escalation and expansion trial that will evaluate safety pharmacodynamics and pharmacokinetics as well as the clinical effects of CA-170 in patients with lymphomas and advanced tumors. Administration of CA-170 shall be in two dose levels in the evaluation of the dedicated mesothelioma cohort.